Despite promising Phase 2 results and an excellent safety profile, the compound could not demonstrate sufficient efficacy in the larger confirmatory trial to justify the investment required for continued pharmaceutical development toward regulatory approval
Yes, the appetite-neutral nature of AOD-9604 allows you to maintain your normal eating patterns and follow your chosen nutrition approach without pharmaceutical interference
Side Effects & Safety Mild GI discomfort most common, usually transient in the first week Slight stimulant effect increased energy/alertness, especially early on Headaches occasional, typically mild and dose-related Mild insomnia if taken too late in the day No human clinical safety data all safety information from preclinical studies and community reports No liver toxicity observed in animal studies at therapeutic doses Unknown drug interactions theoretically could interact with NAD+-dependent pathways Core Supplies for This Protocol The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking
Contact us for more information, or schedule your online consultation
This data helps your provider make better-informed decisions about dose adjustments and supportive strategies tailored to your response pattern